BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Cash-Strapped Iomai Jumps on $189M Buyout Bid by Intercell
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cash-Strapped Iomai Jumps on $189M Buyout Bid by Intercell
May 14, 2008
By
Jennifer Boggs
and
Cormac Sheridan
No Comments
Shares of Iomai Corp. surged more than 117 percent after the firm agreed to be acquired by Austrian vaccines maker Intercell AG in a deal valued at about $189 million. (BioWorld Today)
BioWorld